Vettz and Papi jump back in for a general overview on an up and coming pharma stock that has the potential to revolutionize chemotherapy. Nucana develops protective moieties called phosphoramidate components for chemotherapy drugs. These moieties change the chemical property of traditional chemotherapy drugs allowing the chemo drugs to enter cancer cells independently of nucleoside transporters (easier entry) and protects them from cancer cells’ defenses called deaminase enzymes, which break down chemotherapy molecules. This allows delivery of active drug faster and more protected for a better response to therapy. Vettz also touches on the current dilemma of Cathie Wood at ARK invest. Currently ARK’s popularity is becoming a bit of a problem as their own size is becoming their worst enemy. You’ll have to listen to find out!